These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 31797488)
1. Triple-negative breast cancer-Role of immunology: A systemic review. Oner G; Altintas S; Canturk Z; Tjalma W; Verhoeven Y; Van Berckelaer C; Berneman Z; Peeters M; Pauwels P; van Dam PA Breast J; 2020 May; 26(5):995-999. PubMed ID: 31797488 [TBL] [Abstract][Full Text] [Related]
2. Triple negative breast cancer - prognostic role of immune-related factors: a systematic review. Stovgaard ES; Nielsen D; Hogdall E; Balslev E Acta Oncol; 2018 Jan; 57(1):74-82. PubMed ID: 29168430 [TBL] [Abstract][Full Text] [Related]
3. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents. Santoni M; Romagnoli E; Saladino T; Foghini L; Guarino S; Capponi M; Giannini M; Cognigni PD; Ferrara G; Battelli N Biochim Biophys Acta Rev Cancer; 2018 Jan; 1869(1):78-84. PubMed ID: 29126881 [TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of TILs as a biomarker in triple-negative breast cancer: what is the role of TILs in TME of TNBC? Zhou Y; Tian Q; Wang BY; Yang J; Zhao SD; Yang J Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2885-2897. PubMed ID: 33877653 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy. Han M; Li J; Wu S; Wu C; Yu Y; Liu Y Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303 [TBL] [Abstract][Full Text] [Related]
6. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902 [TBL] [Abstract][Full Text] [Related]
7. Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer. Zhu X; Zhang Q; Wang D; Liu C; Han B; Yang JM Cancer Biol Ther; 2019; 20(8):1105-1112. PubMed ID: 30929569 [No Abstract] [Full Text] [Related]
8. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974 [TBL] [Abstract][Full Text] [Related]
9. Essential amino acid metabolism-related molecular classification in triple-negative breast cancer. Zhao Y; Pu C; Jiao D; Zhu J; Guo X; Liu Z Epigenomics; 2021 Aug; 13(16):1247-1268. PubMed ID: 34448400 [TBL] [Abstract][Full Text] [Related]
10. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. Isaacs J; Anders C; McArthur H; Force J Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085 [TBL] [Abstract][Full Text] [Related]
11. Role of inflammatory infiltrates in triple negative breast cancer. Matsumoto H; Koo SL; Dent R; Tan PH; Iqbal J J Clin Pathol; 2015 Jul; 68(7):506-10. PubMed ID: 25750267 [TBL] [Abstract][Full Text] [Related]
12. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women. O'Meara T; Safonov A; Casadevall D; Qing T; Silber A; Killelea B; Hatzis C; Pusztai L Breast Cancer Res Treat; 2019 May; 175(1):247-259. PubMed ID: 30725384 [TBL] [Abstract][Full Text] [Related]
13. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168 [TBL] [Abstract][Full Text] [Related]
14. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival. Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963 [TBL] [Abstract][Full Text] [Related]
15. Immune-related biomarkers in triple-negative breast cancer. Zhang J; Tian Q; Zhang M; Wang H; Wu L; Yang J Breast Cancer; 2021 Jul; 28(4):792-805. PubMed ID: 33837508 [TBL] [Abstract][Full Text] [Related]
16. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways. Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082 [TBL] [Abstract][Full Text] [Related]
17. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy. Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323 [TBL] [Abstract][Full Text] [Related]
18. [Progress of Tumor Infiltrating Lymphocytes in Immunotherapy of Triple Negative Breast Cancer]. Zhao JL; Wang XJ; Cao X; Sun Q Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Jun; 43(3):475-480. PubMed ID: 34238426 [TBL] [Abstract][Full Text] [Related]
19. Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC). Blackley EF; Loi S Breast; 2019 Nov; 48 Suppl 1():S44-S48. PubMed ID: 31839159 [TBL] [Abstract][Full Text] [Related]
20. Targeting triple-negative breast cancer: A clinical perspective. Popovic LS; Matovina-Brko G; Popovic M; Punie K; Cvetanovic A; Lambertini M Oncol Res; 2023; 31(3):221-238. PubMed ID: 37305385 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]